Skip to main content
. 2014 Nov 26;16(1):52–59. doi: 10.4161/15384047.2014.986982

Figure 2.

Figure 2.

Caspase 3 activation of MCF-7 breast cancer cells treated by TAC and SGK1 inhibitor EMD638683. After 2, 4, 6, and 24h exposure in the absence (control) or presence of 100 nM TAC, 50 μM EMD638683 or TAC+EMD638683 in the presence or absence of 1 μM flutamide, or 1 μl solvent (DMSO), cells were stained with conjugated inhibitor of active Caspase-3 (FITC-DEVD-FMK) and measured by FACS. Graph is showing arithmetic means ± SEM (n = 6) of the percentage gated MCF-7 cells. ** (P < 0 .01) and *** (P < 0.001) indicate significant differences to respective value of untreated control (unpaired t-test). ## (P < 0 .01) indicates significant differences of TAC+EMD638683 treated cells to respective values of TAC-treated cells. Note that no differences are observed between presence or absence of 1 μM flutamide.